2023-01-26 01:00:00

GenKOre Announces Collaboration with a US-based Company on In vivo Gene-editing Therapy

Logo PR Newswire
PR Newswire

SEOUL, South Korea, Jan. 25, 2023 /CNW/ -- GenKOre, Inc., a Korea-based biotech company with hypercompact CRISPR-Cas tools, announced that it has entered into a strategic research collaboration with a US-based biopharma company for the development of in vivo gene editing therapies. This collaboration will utilize GenKOre's proprietary CRISPR-Cas platform, TaRGET (Tiny nuclease, augment RNA-based Genome Editing Technology). The TaRGET platform is distinct from the most popular genome editing technology, CRISPR-Cas9, in that the whole editing module can be delivered with a single AAV vector. Based on their TaRGET platform, GenKOre has developed different modalities of editing tools including TaRGET-CUT, TaRGET-Adenine Base Editing (ABE), TaRGET-AI (Gene Activation and Inhibition system). and TaRGET-FREE (Gene knock-in) .

"This collaboration reflects the strength and potential utility of TaRGET platform in the application of in vivo gene-editing therapy", said Yong-Sam Kim, CEO of GenKOre. "Not only will this collaboration provide an opportunity to validate the applicability of TaRGET platform to in vivo therapy, but we will also expand the utility of our technologies to a wider spectrum of rare diseases." The collaboration was built on the mutual interest in forging transformative therapeutics for patients with rare diseases.

Under the terms of the agreement, GenKOre will receive up to 300 million USD including an upfront, option exercise fees and milestone payments upon successful achievement of R&D and commercial milestones across two in vivo disease targets. In addition, GenKOre will receive research funding and tiered royalties up to a double-digit percentage of net sales.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/genkore-announces-collaboration-with-a-us-based-company-on-in-vivo-gene-editing-therapy-301725677.html

SOURCE GenKOre

Logo PR Newswire
HealthPress Release2023-01-25 23:00:00
DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "Global Gene Therapy Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's...

Logo PR Newswire
HealthPress Release2023-01-25 18:50:00
DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "CRISPR Technology: Global Markets" report has been added to ResearchAndMarkets.com's offering. A $9.2 Billion...

Logo PR Newswire
HealthPress Release2023-01-25 15:13:00
MILWAUKEE, Jan. 25, 2023 /PRNewswire/ -- GenoPalate, Inc., a Milwaukee -based nutritional genomics company, is launching GenoVit, a new line of personalized...

Logo PR Newswire
NANJING, China, Jan. 25, 2023 /PRNewswire/ -- As the tissue engineering and regenerative treatment industry has shown tremendous potential in clinical...

Logo PR Newswire
HealthPress Release2023-01-25 18:00:00
BOSTON and ATLANTA, Jan. 25, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 13:02:00
Capital investment led by John Ballantyne will support optimization of the company's muscle-specific non-viral gene therapy platform, moving closer to...

Logo GlobeNewswire
SciencePress Release2023-01-25 12:45:00
Boca Raton, Florida, Jan. 25, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the Company), a clinical-stage immunology company focused on...

Logo GlobeNewswire
SciencePress Release2023-01-25 12:00:00
BOCA RATON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (First Wave BioPharma or the Company), a clinical-stage...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-25 15:31:00
Investment from Leading Duchenne Organization Contributes To Seed Funding Round Totaling Over $5 Million, Builds on Earlier PPMD Investment Which Facilitated...

Logo PR Newswire
HealthPress Release2023-01-24 10:56:00
Two successful exits – Syndesi and BioPhero Four portfolio companies reported clinical data from first in class targets (Galecto, NMD Pharma, Heparegenix and...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 16:04:00
Collaboration Expected to Enhance Clinical Providers' Access to Comprehensive Genomic Testing VieCure today announced a new collaboration with Labcorp to...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 10:00:00
ATUM, a global specialist and industry leader in bioengineering solutions, today announced the signing of a full licensing agreement for the Leap-In...

Logo EIN Presswire
New appointments and partnerships will focus on supporting industry, science and policy collaboration in tech-focused sectors

Logo GlobeNewswire
SciencePress Release2023-01-25 13:00:00
AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage...

Logo PR Newswire
TechnologyPress Release2023-01-25 13:00:00
PALO ALTO, Calif., Jan. 25, 2023 /PRNewswire/ -- Deep Forest Sciences, Inc., a startup that accelerates chemical matter discovery and optimization is...

Logo PR Newswire
HealthPress Release2023-01-24 14:00:00
BOSTON, Jan. 24, 2023 /PRNewswire/ -- Syner-G BioPharma Group ("Syner-G" or the "Company"), a leading provider of integrated pharmaceutical science and...

Logo GlobeNewswire
SciencePress Release2023-01-24 21:10:00
Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 24, 202 3 GENFIT (Nasdaq and Euronext: GNFT), a late-stage...

Logo PR Newswire
HealthPress Release2023-01-25 14:00:00
SAN DIEGO, Jan. 25, 2023 /PRNewswire/ -- Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access,...

Logo Benzinga
Business / FinanceBy Globe Newswire2023-01-25 09:00:00
- Claus Andersson, PhD, joins Rewinds Board of Directors Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics, a company developing first-in-class...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:00:00
First Immunosynthen ADC product candidate enters the clinic CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a...